Date: 2016-05-09
Type of information: Opening of new premises
Compound:
Company: Fujifilm Diosynth Biotechnologies (USA - NC)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism:
Disease:
Details: * On May 9, 2016, FUJIFILM Diosynth Biotechnologies U.S.A., announced that the company has completed the construction of a new three-story, 62,000 square foot state-of-the-art facility in Research Triangle Park, North Carolina. The new building, called BioProcess Innovation Center, houses the company’s Process and Analytical Research and Development, Process Sciences and Stability groups. These will concentrate on delivering excellence in process invention, design and development and process and product characterization for our clients. They will also continue to innovate to further develop systems and approaches which rapidly lead to efficient, robust and high quality biomanufacturing processes. Fujifilm Diosynth Biotechnologies has combined experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect cell line systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. The company is also located in Billingham, UK and in College Station, Texas.
Financial terms:
Latest news:
